MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Moderna (MRNA) shares rose 4% following positive preliminary Phase IV data for its 2025-2026 Spikevax COVID-19 vaccine, which demonstrated an 8-fold increase in neutralizing antibodies against the LP.8.1 variant with a consistent safety profile. This data reinforces the FDA's recent approval of the updated formula and offers a positive catalyst for MRNA, despite its significant year-to-date underperformance, as it competes with other recently approved updated COVID-19 vaccines from Pfizer/BioNTech and Novavax.

Analysis

Moderna's shares (MRNA) experienced a 4% uplift following the release of positive preliminary data from a Phase IV study of its updated 2025-2026 Spikevax COVID-19 vaccine. The study demonstrated a significant immune response, with a greater than 8-fold increase in neutralizing antibodies against the LP.8.1 variant, and a safety profile consistent with previous studies, alleviating concerns about new side effects. This result is particularly noteworthy as it quantitatively surpasses the 4-fold antibody increase reported by competitors Pfizer/BioNTech for their updated Comirnaty vaccine, positioning Moderna with a potential clinical advantage. This data reinforces the FDA's recent approval of the vaccine, which targets adults 65 and older and at-risk individuals in younger age groups. However, this positive news must be contextualized by the stock's severe year-to-date underperformance, having plunged 40.3% against a 2.8% growth for the industry, reflecting broader market headwinds and a more constrained commercial opportunity for COVID-19 vaccines compared to prior years.

Key Decisions for Investors

• Consider that Moderna's superior immunogenicity data, showing an 8-fold antibody increase versus Pfizer's 4-fold, may translate into a stronger competitive position and market share capture in the 2025-26 vaccination season.
• Investors should weigh this positive clinical catalyst against the stock's significant -40.3% year-to-date decline and the limited commercial market, which is now primarily focused on adults over 65 and at-risk individuals.
• Monitor the market adoption of Moderna's new refrigerator-stable mNexspike vaccine, as its logistical advantages could serve as a key differentiator against both mRNA and non-mRNA competitors in the long term.